These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11724447)

  • 1. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.
    Spitsin S; Hooper DC; Leist T; Streletz LJ; Mikheeva T; Koprowskil H
    Mult Scler; 2001 Oct; 7(5):313-9. PubMed ID: 11724447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.
    Scott GS; Spitsin SV; Kean RB; Mikheeva T; Koprowski H; Hooper DC
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16303-8. PubMed ID: 12451183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of multiple sclerosis with inosine.
    Markowitz CE; Spitsin S; Zimmerman V; Jacobs D; Udupa JK; Hooper DC; Koprowski H
    J Altern Complement Med; 2009 Jun; 15(6):619-25. PubMed ID: 19425822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.
    Spitsin S; Markowitz CE; Zimmerman V; Koprowski H; Hooper DC
    J Hum Hypertens; 2010 May; 24(5):359-62. PubMed ID: 19865105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Uric acid and multiple sclerosis].
    Mattle HP; Lienert C; Greeve I
    Ther Umsch; 2004 Sep; 61(9):553-5. PubMed ID: 15493114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.
    Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J
    Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis.
    Toncev G
    Vojnosanit Pregl; 2006 Oct; 63(10):879-82. PubMed ID: 17121380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis.
    Dujmovic I; Pekmezovic T; Obrenovic R; Nikolić A; Spasic M; Mostarica Stojkovic M; Drulovic J
    Clin Chem Lab Med; 2009; 47(7):848-53. PubMed ID: 19496733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum uric acid and multiple sclerosis.
    Rentzos M; Nikolaou C; Anagnostouli M; Rombos A; Tsakanikas K; Economou M; Dimitrakopoulos A; Karouli M; Vassilopoulos D
    Clin Neurol Neurosurg; 2006 Sep; 108(6):527-31. PubMed ID: 16202511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum uric acid and multiple sclerosis.
    Sotgiu S; Pugliatti M; Sanna A; Sotgiu A; Fois ML; Arru G; Rosati G
    Neurol Sci; 2002 Oct; 23(4):183-8. PubMed ID: 12536287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associated Inosine to interferon: results of a clinical trial in multiple sclerosis.
    Muñoz García D; Midaglia L; Martinez Vilela J; Marín Sánchez M; López González FJ; Arias Gómez M; Dapena Bolaño D; Iglesias Castañón A; Alonso Alonso M; Romero López J
    Acta Neurol Scand; 2015 Jun; 131(6):405-10. PubMed ID: 25313094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
    Gonsette RE; Sindic C; D'hooghe MB; De Deyn PP; Medaer R; Michotte A; Seeldrayers P; Guillaume D;
    Mult Scler; 2010 Apr; 16(4):455-62. PubMed ID: 20200198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.
    Constantinescu CS; Freitag P; Kappos L
    Mult Scler; 2000 Dec; 6(6):378-81. PubMed ID: 11212132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica.
    Peng F; Yang Y; Liu J; Jiang Y; Zhu C; Deng X; Hu X; Chen X; Zhong X
    Eur J Neurol; 2012 Feb; 19(2):277-83. PubMed ID: 21801283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
    Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
    Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uric acid: a potential biomarker of multiple sclerosis and of its disability.
    Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB
    Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of uric acid in multiple sclerosis.
    Spitsin S; Koprowski H
    Curr Top Microbiol Immunol; 2008; 318():325-42. PubMed ID: 18219824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases.
    Peng F; Zhang B; Zhong X; Li J; Xu G; Hu X; Qiu W; Pei Z
    Mult Scler; 2008 Mar; 14(2):188-96. PubMed ID: 17942520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum uric acid levels in patients with myasthenia gravis are inversely correlated with disability.
    Yang D; Weng Y; Lin H; Xie F; Yin F; Lou K; Zhou X; Han Y; Li X; Zhang X
    Neuroreport; 2016 Mar; 27(5):301-5. PubMed ID: 26836463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric acid levels in sera from patients with multiple sclerosis.
    Drulović J; Dujmović I; Stojsavljević N; Mesaros S; Andjelković S; Miljković D; Perić V; Dragutinović G; Marinković J; Lević Z; Mostarica Stojković M
    J Neurol; 2001 Feb; 248(2):121-6. PubMed ID: 11284129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.